<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04957758</url>
  </required_header>
  <id_info>
    <org_study_id>OPP-102</org_study_id>
    <nct_id>NCT04957758</nct_id>
  </id_info>
  <brief_title>Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Controlled, Double-Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray in Subjects With Neurotrophic Keratopathy (the Olympia Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oyster Point Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oyster Point Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and effectiveness of OC-01&#xD;
      (varenicline) nasal spray as compared to placebo nasal spray for complete resolution of&#xD;
      corneal staining (0 mm lesion and no residual staining) in subjects with Stage 1 (corneal&#xD;
      epithelial hyperplasia/punctate keratopathy) neurotrophic keratopathy (NK) in one or both&#xD;
      eyes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol OPP-102 is a Phase 2, multicenter, randomized, controlled, double- masked study&#xD;
      designed to evaluate the safety and efficacy of OC-01 (varenicline) nasal spray in subjects&#xD;
      with NK. Approximately 100 subjects at least 18 years of age with a physicians' diagnosis of&#xD;
      Stage 1 NK as defined by the Mackie Criteria and meeting all other study eligibility criteria&#xD;
      will be randomized 1:1 and will receive OC-01 (varenicline)/ nasal spray or placebo nasal&#xD;
      spray for 8 weeks three times daily (TID) as follows:&#xD;
&#xD;
        -  OC-01 (varenicline) nasal spray, 1.2 mg/mL&#xD;
&#xD;
        -  Placebo (vehicle control) nasal spray All doses will be delivered as a 50 microliter&#xD;
           (µL) nasal spray.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of subjects who achieve complete resolution of corneal staining (defined as complete resolution of corneal staining (0 mm lesion and no residual staining) in subjects with Stage 1 NK at Week 8 as measured by the central reading center.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Primary Endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of subjects that change to Stage 2 Persistent Epithelial Defect (PED) NK at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Secondary Endpoint #1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in corneal sensitivity at Week 8 • Improvement in corneal sensitivity at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Secondary Endpoint #2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neurotrophic Keratopathy</condition>
  <arm_group>
    <arm_group_label>OC-01 (varenicline) nasal spray, 1.2 mg/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OC-01 (varenicline) nasal spray, 1.2 mg/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (vehicle control) nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (vehicle control) nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC-01 (varenicline) nasal spray 1.2 mg/ml</intervention_name>
    <description>OC-01</description>
    <arm_group_label>OC-01 (varenicline) nasal spray, 1.2 mg/mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (vehicle) nasal spray</intervention_name>
    <description>Placebo (vehicle)</description>
    <arm_group_label>Placebo (vehicle control) nasal spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be at least 18 years of age at Visit 1.&#xD;
&#xD;
          2. Patients with Stage 1 (corneal epithelial hyperplasia/punctate keratopathy) NK in one&#xD;
             or both eyes, as defined by the Mackie Criteria.&#xD;
&#xD;
          3. Evidence of decreased corneal sensitivity (≤ 4 cm using the Cochet-Bonnet&#xD;
             aesthesiometer) in at least 1 corneal quadrant.&#xD;
&#xD;
          4. Schirmer's test without anesthesia &gt;3 mm/ 5 minutes in the affected eye with a cotton&#xD;
             swab nasal stimulation Schirmer's Test score at least 7 mm greater in the same eye&#xD;
&#xD;
          5. Have provided verbal and written informed consent.&#xD;
&#xD;
          6. If a female is of childbearing potential, they must: use an acceptable means of birth&#xD;
             control (acceptable methods of contraception include hormonal - oral, implantable,&#xD;
             injectable, or transdermal contraceptives, mechanical - spermicide in conjunction with&#xD;
             a barrier such as a diaphragm or condom, IUD, or surgical sterilization of partner),&#xD;
             and have a negative urine pregnancy test on Day 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have Stage 2 or Stage 3 NK affecting one or both eyes.&#xD;
&#xD;
          2. Have ocular graft versus host disease or Stevens-Johnson syndrome.&#xD;
&#xD;
          3. Have any active ocular infection (COVID-19 conjunctivitis, bacterial, viral, fungal,&#xD;
             or protozoal) or active ocular inflammation not related to NK in the affected eye.&#xD;
&#xD;
          4. Have any other ocular disease requiring topical ocular treatment in the affected eye&#xD;
             during the study treatment period. No topical ocular treatments, other than&#xD;
             preservative free artificial tears can be utilized.&#xD;
&#xD;
          5. Have used Restasis® or Xiidra® Cequa and steroids in the past 30 days prior to Visit&#xD;
             1.&#xD;
&#xD;
          6. Have severe blepharitis and/or severe meibomian gland disease in the study eye.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marian Macsai</last_name>
    <phone>(312) 259-2477</phone>
    <email>mmacsai@oysterpointrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Los Angeles California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mission Hills California</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Miami Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Louisville KY</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Union Kentucky</name>
      <address>
        <city>Union</city>
        <state>Kentucky</state>
        <zip>41091</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bowie, Maryland</name>
      <address>
        <city>Bowie</city>
        <state>Maryland</state>
        <zip>20716</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henderson Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lynchburg Virginia</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

